1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 3: Significant predictors of cost
P Value Partial Eta² Exponentiated β-Coefficient (95% CI)^{^b}
Primary analysis: all ACLVO^{^a} (n = 341) 
    FIV (mL) <.0001 20.87% 1.0037 (1.0029–1.0048)
    PH types 1 and 2 <.0001 5.22% 1.6399 (1.3050–2.0610)
    NIHSS .0024 2.76% 1.0161 (1.0057–1.0266)
    Obstructive sleep apnea .0040 2.48% 1.3391 (1.0981–1.6329)
    Age (yr) .0089 2.06% 0.9946 (0.9906–0.9986)
    Ipsilateral carotid stenosis .0195 1.65% 1.1902 (1.0285–1.3774)
Subgroup analysis by treatment group 
    Endovascular therapy (n = 133) 
        FIV (mL) .0003 10.03% 1.0024 (1.0011–1.0037)
        PH type 1 .0006 9.24% 2.4942 (1.4926–4.1680)
        Obstructive sleep apnea .0018 7.71% 1.5211 (1.1727–1.9730)
        NIHSS .0120 5.08% 1.0206 (1.0046–1.0368)
        Ipsilateral carotid stenosis .0290 3.85% 1.2481 (1.0234–1.5221)
        mTICI score^{^c} .0364 1.79% Multilevel variable
    IV tPA-only (n = 61) 
        FIV (mL) <.0001 29.11% 1.0043 (1.0025–1.0060)
        NIHSS .0300 7.99% 1.0273 (1.0273–1.0524)
    No reperfusion therapy (n = 147) 
        FIV (mL) <.0001 27.92% 1.0042 (1.0031–1.0053)
        PH types 1 and 2 .0005 8.37% 2.6371 (1.5458–4.4988)
        Obstructive sleep apnea .0300 3.29% 1.5057 (1.0407–2.1784)
        Age (yr) .0330 3.20% 0.9925 (0.9857–0.9937)
↵a Controlled for treatment type: endovascular, IV-tPA, and no reperfusion therapy.
↵b The exponentiated β-coefficient represents the multiplicative change in cost associated with an increase in 1 unit of a continuous variable (or the presence of a categoric variable), while holding all other variables constant.
↵c Multilevel variable with F-distribution.